PROCEPT BioRobotics CorporationPRCT stock score: 51/100
$25.75 · +2.26% · Scored Nov 19, 2026
- Technical
- 52
- Fundamental
- 50
- News
- —
The reading
PROCEPT BioRobotics (PRCT) scores 51 out of 100, which reads neutral, higher than 50% of Healthcare stocks and 47% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 50, technicals 52.
Among the fundamentals, Revenue Growth (5-Year) at 100 and Quick Ratio at 99 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 72 and contrarian oscillators 29 — a split worth reading before trusting the technical total.
Since Aug 22, 2026 the composite has ranged from 34 to 51, and it is up 11 points over the period.
About PROCEPT BioRobotics
PROCEPT BioRobotics (PRCT) is a U.S. surgical robotics company that develops systems for treating benign prostatic hyperplasia, the noncancerous enlargement of the prostate that causes urinary symptoms in many older men. Its HYDROS and earlier AquaBeam robotic systems deliver Aquablation therapy, which uses a heat-free waterjet guided by real-time ultrasound imaging to remove prostate tissue according to a surgeon’s plan, with HYDROS adding artificial intelligence to help with treatment planning. The approach is designed to treat prostates of many sizes and shapes while preserving functions that other surgeries can affect. Customers are hospitals and urologists in the United States, with international expansion starting in the United Kingdom. PROCEPT earns money from selling robotic systems, from single-use handpieces and other consumables used in every procedure and from service contracts, so recurring revenue grows as procedure volumes rise.
PROCEPT competes with traditional prostate surgery such as transurethral resection, with laser procedures and with less invasive treatments such as Boston Scientific’s Rezum and UroLift. Its edge rests on a robotic, image-guided procedure supported by a growing body of clinical studies, a guideline recommendation from European urologists and an installed base of systems that drives consumable sales. Investors who follow PRCT stock tend to watch system placements, procedure volumes and handpiece revenue. Utilization of installed systems and surgeon training are closely followed. Reimbursement rates, international expansion, gross margins, operating losses and cash use are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward PRCT’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
50Pulling it up
5-year revenue growth analyzes long-term sales trajectory and consistency.
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
Operating margins measure profitability after operating expenses.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
64Pulling it up
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
- TRIX100
TRIX is a triple-smoothed momentum oscillator.
- VWAP100
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 56 | 1 |
| Daily | 64 | 3 |
| Weekly | 44 | 2 |
| Monthly | 39 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 51 |
| Nov 18, 2026 | 51 |
| Nov 17, 2026 | 51 |
| Nov 16, 2026 | 51 |
| Nov 15, 2026 | 51 |
| Nov 14, 2026 | 51 |
| Nov 13, 2026 | 51 |
| Nov 12, 2026 | 50 |
| Nov 11, 2026 | 43 |
| Nov 10, 2026 | 43 |
| Nov 8, 2026 | 40 |
| Nov 7, 2026 | 40 |
| Nov 6, 2026 | 40 |
| Nov 5, 2026 | 41 |
| Nov 4, 2026 | 40 |
| Nov 3, 2026 | 40 |
| Nov 2, 2026 | 38 |
| Nov 1, 2026 | 38 |
| Oct 31, 2026 | 38 |
| Oct 30, 2026 | 38 |
| Oct 29, 2026 | 40 |
| Oct 28, 2026 | 41 |
| Oct 27, 2026 | 39 |
| Oct 26, 2026 | 40 |
| Oct 25, 2026 | 40 |
| Oct 24, 2026 | 40 |
| Oct 23, 2026 | 40 |
| Oct 22, 2026 | 40 |
| Oct 21, 2026 | 38 |
| Oct 20, 2026 | 38 |
| Oct 19, 2026 | 37 |
| Oct 18, 2026 | 35 |
| Oct 17, 2026 | 35 |
| Oct 16, 2026 | 35 |
| Oct 15, 2026 | 36 |
| Oct 14, 2026 | 35 |
| Oct 13, 2026 | 38 |
| Oct 12, 2026 | 39 |
| Oct 11, 2026 | 38 |
| Oct 10, 2026 | 38 |
| Oct 9, 2026 | 38 |
| Oct 8, 2026 | 37 |
| Oct 7, 2026 | 37 |
| Oct 6, 2026 | 36 |
| Oct 5, 2026 | 36 |
| Oct 4, 2026 | 35 |
| Oct 3, 2026 | 35 |
| Oct 2, 2026 | 35 |
| Oct 1, 2026 | 35 |
| Sep 30, 2026 | 36 |
| Sep 29, 2026 | 36 |
| Sep 28, 2026 | 35 |
| Sep 27, 2026 | 35 |
| Sep 26, 2026 | 35 |
| Sep 25, 2026 | 34 |
| Sep 24, 2026 | 35 |
| Sep 23, 2026 | 36 |
| Sep 22, 2026 | 35 |
| Sep 21, 2026 | 35 |
| Sep 20, 2026 | 35 |
| Sep 19, 2026 | 35 |
| Sep 18, 2026 | 36 |
| Sep 17, 2026 | 35 |
| Sep 16, 2026 | 35 |
| Sep 15, 2026 | 35 |
| Sep 14, 2026 | 37 |
| Sep 13, 2026 | 36 |
| Sep 12, 2026 | 36 |
| Sep 11, 2026 | 36 |
| Sep 10, 2026 | 35 |
| Sep 9, 2026 | 36 |
| Sep 8, 2026 | 38 |
| Sep 7, 2026 | 41 |
| Sep 6, 2026 | 40 |
| Sep 5, 2026 | 40 |
| Sep 4, 2026 | 40 |
| Sep 3, 2026 | 39 |
| Sep 2, 2026 | 40 |
| Sep 1, 2026 | 38 |
| Aug 31, 2026 | 37 |
| Aug 30, 2026 | 37 |
| Aug 29, 2026 | 37 |
| Aug 28, 2026 | 36 |
| Aug 27, 2026 | 36 |
| Aug 26, 2026 | 38 |
| Aug 25, 2026 | 39 |
| Aug 24, 2026 | 38 |
| Aug 23, 2026 | 39 |
| Aug 22, 2026 | 40 |
Key facts
- Market cap
- $1.5B
- Sector
- Healthcare
- Industry
- Medical Devices
- Beta
- 0.84
- Risk grade (1–10)
- 9
- Next earnings
- Nov 4, 2026
Medical Device peers
| Company | Market cap | Score |
|---|---|---|
| INSP Inspire Medical Systems | $1.6B | 60 |
| BFLY Butterfly Network | $1.6B | 47 |
| ENOV Enovis | $1.5B | 47 |
| CNMD CONMED | $1.4B | 57 |
| NVCR NovoCure | $1.2B | 44 |
| TNDM Tandem Diabetes Care | $1.2B | 38 |
Questions
What is PRCT's stock rating today?
PRCT scores 51/100 (Neutral) as of Nov 19, 2026: technical 52, fundamental 50. Scores are recomputed every night.
What does PROCEPT BioRobotics do?
PROCEPT BioRobotics (PRCT) is a U.S. surgical robotics company that develops systems for treating benign prostatic hyperplasia, the noncancerous enlargement of the prostate that causes urinary symptoms in many older men.
Is PRCT stock a buy?
The score is not a buy or sell recommendation. A 51 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the PRCT score calculated?
100 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/prct/"><img src="https://stocksscores.com/stocks/prct/badge.svg" alt="PRCT stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/prct/)